Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum

Human Gene Therapy

Volumn 7, Issue 9, 1996, Pages 1095-1101

  Pensiero, Michael N ^a   Wysocki, Christian A ^a   Nader, Kellie ^a   Kikuchi, Gary E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN 3T3; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RETROVIRUS; SERUM; VIRUS GENE; VIRUS INACTIVATION;

ANIMALIA; MURINAE; MURINE LEUKEMIA VIRUS; MUSTELA VISON; UNIDENTIFIED RETROVIRUS;

EID: 0029893033     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.9-1095     Document Type: Article

References (26)

1. BARCLAY, A.N., BEYERS, A.D., BIRKELAND, M.L., BROWN, M.H., DAVIS, M.H., SOMOZA, C., and WILLIAMS, A.F. (1994). The Leucocyte Antigen Facts Book. (Academic Press, Harcourt Brace & Co., New York).
2. BARTHOLOMEW, R.M., and ESSER, A.F. (1977). The first complement component: evidence for an equilibrium between C1s free in serum and C1s bound in the C1 complex. J. Immunol. 119, 1916-1922.
3. BARTHOLOMEW, R.M., and ESSER, A.F. (1980). Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes. Biochemistry 19, 2847-2853.
4. BARTHOLOMEW, R.M., ESSER, A.F., and MULLER-EBERHARD, H.J. (1978). Lysis of oncornaviruses by human serum. J. Exp. Med. 147, 844-853.
5. COSSET, F-L, TAKEUCHI, Y., BATTINI, J-L, WEISS, R.A., and COLLINS, M.K.L. (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
6. CULVER, K.W., VAN GILDER, J., CARLSTROM, T., PRADOS, M., and LINK, C.J.J. (1995). Gene Therapy for Brain Tumors. In Somatic Gene Therapy. P.L., Chang, eds. (CRC Press, Tokyo) pp. 243-262.
7. DAVIES, A., SIMMONS, D.L., HALE, G., HARRISON, R.A., TIGHE, H., LACHMANN, P.J., and WALDMANN, H. (1989). CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170, 637-654.
8. GALILI, U., and SWANSON, K. (1991). Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc. Natl. Acad. Sci. USA. 88, 7401-7404.
9. GALILI, U., SHOHET, S.B., KOBRIN, E., STULTS, C.L.M., and MACHER, B.A. (1988). Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263, 17755-17762.
10. JOZIASSE, D.H., SHAPER, J.H., WANG JABS, E., and SHAPER, N.L. (1991). Characterization of an α1-3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene. J. Biol. Chem. 266, 6991-6998.
11. KOTANI, H., NEWTON III, P.B., ZHANG, S., CHIANG, Y.L., OTTO, E., WEAVER, L., BLAESE, R.M., ANDERSON, W.F., and MCGARRITY, G.J. (1994). Improved methods of retro viral vector transduction and production for gene therapy. Hum. Gene Ther. 5, 19-28.
12. LUBLIN, D.M., and ATKINSON, J.P. (1989). Decay-accelerating factor:biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35-58.
13. MARSCHANG, P., SODROSKI, J., WURZNER, R., and DIERICH, M.P. (1995). Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25, 285-290.
14. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell Biol. 6, 2895-2902.
15. MILLER, A.D., and VERMA, J.M. (1984). Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1). J. Virol. 49, 214-222.
16. PARKER, W., BRUNO, D., HOLZKNECHT, Z.E., and PLATT, J.L. (1994). Characterization and affinity isolation of xenoreactive human natural antibodies. J. Immunol. 153, 3791-3803.
17. PEAR, W.S., NOLAN, G.P., SCOTT, M.L., and BALTIMORE, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396.
18. REIN, A., MIRRO, J., GORDON HAYNES, J., ERNST, S.M., and NAGASHIMA, K. (1994). Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membranes fusion capability of the murine leukemia virus env protein. J. Virol. 68, 1773-1781.
19. ROTHER, R.P., FODOR, W.L., SPRINGHORN, J.P., BIRKS, W.B., SETTER, E., SANDRIN, M.S., SQUINTO, S.P., and ROLLINS, S.A. (1995b). A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J. Exp. Med. 182, 1345-1355.
20. ROTHER, R.P., SQUINTO, S.P., MASON, J.M., and ROLLINS, S.A. (1995a). Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. 6, 429-435.
21. RUSSELL, D.W., BERGER, M.S., and MILLER, A.D. (1995). The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6, 635-641.
22. SANDRIN, M.S., and McKENZIE, I.F.C. (1994). Galα(1,3)Gal, the major xenoantigen(s) recognized in pigs by human natural antibodies. Immunol. Rev. 141, 169-190.
23. SHERWIN, S., BENVENISTE, R.E., and TODARO, G.J. (1978). Complement-mediated lysis of type-C virus: Effect of primate and human sera on various retroviruses. Int. J. Cancer 21, 6-11.
24. TAKEUCHI, Y., COSSET, F.C., LACHMANN, P.J., OKADA, H., WEISS, R.A., and COLLINS, M.K.L. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
25. WELSH, R.M., JR., COOPER, N.R., JENSEN, F.C., and OLDSTONE, M.B.A. (1975). Human serum lyses RNA tumor viruses. Nature 257, 612-614.
26. WHALEY, K., and LEMERCIER, C. (1993). In Humoral Factors. The Natural Immune System. E. Sim, ed. (IRL Press, New York) pp. 121-150.